Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas

Clinical trial NCT06176027 · RECRUITING

Trial details

NCT number: NCT06176027
Sponsor: Navy General Hospital, Beijing
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Relapsed Peripheral T-Cell Lymphomas Refractory Peripheral T-Cell Lymphomas

Start date: 2024-10-01
Primary completion: 2028-09-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.